Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1175 USD | -1.26% | +0.34% | +657.96% |
Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
Apr. 19 | Top Premarket Decliners | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 4 | 100.0 % | 24 | 100.0 % | +454.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 24 | 100.0 % | +454.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Chief Tech/Sci/R&D Officer | 60 | 16-01-31 | |
Malek Chamoun
PRN | Corporate Officer/Principal | 39 | Jan. 24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Chief Tech/Sci/R&D Officer | 60 | 16-01-31 | |
Rabi Kiderchah
BRD | Director/Board Member | 51 | 21-10-30 |
Andrew Keller
BRD | Director/Board Member | 70 | 22-02-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 994,529 | 900,534 ( 90.55 %) | 0 | 90.55 % |
Stock B | 0 | 10,000 | 0 | 0 |
Company contact information
Sunshine Biopharma, Inc.
1177 Avenue of the Americas 5th Floor
10036, New York
+
http://www.sunshinebiopharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- SBFM Stock
- SBFM Stock
- Company SUNE BIOP